Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine

Pharmacopsychiatry

Volumn 30, Issue 6, 1997, Pages 263-265

  Normann, C ^a   Hesslinger, B ^a   Frauenknecht, S ^a   Berger, M ^a   Walden, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LEVODOPA; MEMANTINE; MIRTAZAPINE; PERGOLIDE MESILATE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEPRESSION; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0031467188     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979504     Document Type: Article

References (29)

1. Ahlskog, J. E., M. D. Muenter: Pergolide: long-term use in Parkinson's disease. Mayo Clinic Proceedings 63 (1988) 979-987
2. Bernheimer, H., W. Birkmayer, O. Hornykiewicz: Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin. Wochenschr. 39 (1961) 1056-1059
3. Birkmayer, W., W. Danielczyk, E. Neumayer: Nucleus ruber and L-dopa psychosis: biochemical postmortem findings. J. Neural. Transm. 35 (1974) 93-116
4. Birkmayer, W., P. Riederer: Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human postmortem findings). J. Neural. Transm. 35 (1975) 175-182
5. Bouchard, R. H., E. Pourcher, P. Vincent: Fluoxetine and extrapyramidal side effects. Am. J. Psychiatry 146 (1989) 1352-1353
6. Dooneief, G., E. Mirabello, K. Bell, K. Marder, Y. Stern, R. Mayeux: An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch. Neurol. 49 (1992) 305-307
7. Factor, S. A., E. S. Molho, G. D. Podskalny, D. Brown: Parkinson's disease: drug induced psychiatric states. Adv. Neurol. 65 (1995) 115-138
8. Fahn, S., L. R. Libsch, R. W. Cutler: Monoamines in the human neostriatum: topographic distribution in normals in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor. J. Neurol. Sci. 14 (1971) 427-455
9. Garcia-Monco, J. C., A. Padierna, M. G. Beldarrain: Selegiline, fluoxetine, and depression in Parkinson's disease. Movement disorders 10 (1995) 352
10. Goldstein, M., R. Frenkel: Inhibition of serotonin by dopa and other catechols. Nature 233 (1971) 179
11. Haddjeri, N., P. Blier, C. de Montigny: Noradrenergic modulation of central serotonergic neurotransmission: Acute and long-term actions of mirtazapine. Intern. Clin. Psychopharm. 10 Suppl. 4 (1995) 11-18
12. Heinz, A., H. Przuntek, G. Winterer, A. Pietzcker: Klinik und Verlauf dopamininduzierter Psychosen unter kontinuierlicher Therapie und ihre Implikationen für die Dopaminhypothese schizophrener Symptomatik. Nervenarzt 66 (1995) 662-669
13. Jansen Steur, E. N. H.: Increase of parkinson disability after fluoxetine medication. Neurology 43 (1993) 211-213
14. Jimenéz-Jimenéz, F. J., J. Tejeiro, G. Martínez-Junquera, F. Cabrera-Valdivia, J. Alarcón, E. García-Albea: Parkinsonism exacerbated by paroxetine. Neurology 44 (1994) 2406
15. Karobath, M., J. Diaz J., M. Huttunen: The effect of L-dopa on the concentrations of tryptophane, tyrosine and serotonine in rat brain. Eur. J. Pharmacol 14 (1971) 393-396
16. Kasper, S.: Clinical efficacy of mirtazapine: a review of metaanalyses of pooled data. Intern. Clin. Psychopharm. 10 (Suppl. 4) (1995) 25-26
17. Klawans, H. L., C. Goetz, P. A. Nausieda: Levodopa-induced dopamine receptor hypersensitivity. Ann. Neurol. 2 (1977) 125-129
18. Lauterbach, E. C.: Dopaminergic Hallucinosis with fluoxetine in Parkinson's disease. Am. J. Psychiatry 150 (1993) 1750
19. Lehmann, J.: Tryptophan malabsorption in levodopa treated parkinsonian patients: effect of tryptophan on mental disturbances. Acta Med. Scan. 194 (1973) 181-189
20. Meltzer, H. Y., J. Kennedy, M. Persa, D. Riley: Plasma clozapine levels and the treatment of L-dopa-induced psychosis in Parkinson's disease. Neuropsychopharmacology 12 (1995) 39-45
21. Monastruc, J. L., B. Chamontin, J. M. Senard: Pseudophaeochromocytoma in a parkinsonian patient treated with fluoxetine plus selegiline. Lancet 341 (1993) 555
22. Moskovitz, C., H. Moses, H. L Klawans: Levodopa-induced psychosis: A kindling phenomenon. Am. J. Psychiatry 135 (1978) 669-675
23. Nausieda, P. A., C. M. Tanner, H. L. Klawans: Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv. Neurol. 37 (1983) 23-32
24. Ng, K. Y., T. N. Chase, R. W. Colburn, I. J. Kopin: L-dopa induced release of cerebral monoamines. Science 170 (1970) 76
25. Roth, B. L., R. D. Ciaranello, H. Y. Metzer: Bindings of typical and atypical antipsychotic agents to transiently expressed 5-HT1 C-receptors. J Pharmacol. Exp. Ther. 260 (1992) 1361-1365
26. Schanberg, S. M.: A study of the transport of 5-hydroxytryptophan und 5-hydroxytryptamine (serotonin) into the brain. J. Pharmacol. Exp. Ther. 139 (1963) 191
27. Schotte, A., P. F. M. Janssen, A. A. Megens, J. E. Leysen: Occupancy of central neurotransmitter receptors by risperidone, clozapine, and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631 (1993) 191-202
28. Schremmer, C., R. Morgenstern, H. Fink, T. Oh: Atypical neuroleptics suppress dopaminergic behavioral supersensitivity. Psychopharmacology 100 (1990) 299-403
29. 2a-adrenoreceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn-Schmiedebergs Arch. Pharm. 350 (1994) 473-481